Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE7A | Q13946 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.46 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.46 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.46 |
| ▸ | USP10 | Q14694 | 1/20 | 0.45 |
| ▸ | USP7 | Q93009 | 1/20 | 0.45 |
| ▸ | USP47 | Q96K76 | 1/20 | 0.45 |
| ▸ | HSPB1 | P04792 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 5/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29662268 | 0.85 | ATM (0.58) | PDE7ATDP1ATMTXNRD1TXNRD3 | |
| SCHEMBL1151368 | 0.85 | ATM (0.58) | PDE7ATDP1ATMTXNRD1TXNRD3 | |
| SCHEMBL31585223 | 0.81 | TXNRD1 (0.42) | PDE7ATDP1TXNRD1TXNRD3TXNRD2 | |
| SCHEMBL23302290 | 0.81 | PDE7A (0.54) | PDE7ATDP1ATMTXNRD1TXNRD3 | |
| SCHEMBL6558543 | 0.81 | PDE7A (0.54) | PDE7ATDP1ATMTXNRD1TXNRD3 | |
| SCHEMBL8973665 | 0.79 | TXNRD1 (0.72) | TDP1TXNRD1TXNRD3TXNRD2MAPT | |
| SCHEMBL7597811 | 0.79 | TSHR (0.62) | TDP1TXNRD1TXNRD3TXNRD2MAPT | |
| SCHEMBL1136130 | 0.78 | PDE7A (0.51) | PDE7ATDP1ATMTXNRD1TXNRD3 | |
| SCHEMBL11144762 | 0.78 | ALDH1A1 (0.59) | PDE7ATDP1TXNRD1TXNRD3TXNRD2 | |
| SCHEMBL16950944 | 0.78 | TXNRD1 (0.46) | PDE7ATDP1TXNRD1TXNRD3TXNRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009115393-A1 | PROCESS FOR THE PREPARATION OF N-(1-PHENYLETHYL)ANILINES, SALTS, AND SOLVATES THEREOF USEFUL AS SEROTONIN 5-HT6 ANTAGONISTS | LABORATORIOS DEL DR. ESTEVE, S. A. (ES) | 2009-09-24 | — | — | WO | disclosed |
| WO-2009115393-A1 | PROCESS FOR THE PREPARATION OF N-(1-PHENYLETHYL)ANILINES, SALTS, AND SOLVATES THEREOF USEFUL AS SEROTONIN 5-HT6 ANTAGONISTS | LABORATORIOS DEL DR. ESTEVE, S. A. (ES) | 2009-09-24 | — | — | WO | disclosed |
| EP-2103596-A1 | Process for the preparation of N-(phenylethyl) anilines salts and solvates thereof useful as serotonin 5-HT6 antagonists | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2009-09-23 | — | — | EP | disclosed |
| EP-2103596-A1 | Process for the preparation of N-(phenylethyl) anilines salts and solvates thereof useful as serotonin 5-HT6 antagonists | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2009-09-23 | — | — | EP | disclosed |
| US-7473701-B2 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2009-01-06 | — | — | US | disclosed |
| US-20050059722-A1 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2005-03-17 | — | — | US | disclosed |
| US-6858638-B2 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2005-02-22 | — | — | US | disclosed |
| EP-1487803-A1 | INDAZOLES SUBSTITUTED WITH AN ANTI-CANCEROUS ACTIVITY | Aventis Pharma S.A. (FR) | 2004-12-22 | — | — | EP | disclosed |
| US-20040106667-A1 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2004-06-03 | — | — | US | disclosed |
| US-6743796-B2 | PSYCHOLOGICAL DISORDERS; SCHIZOPHRENIA; PARKINSON'S DISEASE | WYETH | 2004-06-01 | — | — | US | disclosed |
| WO-2003078402-A1 | INDAZOLES SUBSTITUTED WITH AN ANTI-CANCEROUS ACTIVITY | AVENTIS PHARMA S.A. (FR) | 2003-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106667-A1 | Substituted indazoles, compositions containing them, method of production and use | ABL1, CDK3, CILK1 | PDE7A 1042/4885TDP1 1505/4885ATM 173/4885 |
| US-20050059722-A1 | Substituted indazoles, compositions containing them, method of production and use | ABL1, CDK3, CILK1 | PDE7A 775/4885TDP1 1512/4885ATM 244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.